<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To alert clinicians to a potential novel adverse drug effect of interferon beta 1a, we herein report a patient with relapsing-remitting multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> who developed <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> following treatment with interferon beta 1a </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0100279'>Ulcerative colitis</z:hpo> persisted despite discontinuation of interferon beta 1a treatment and switching the patient to glatiramer <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Tacrolimus (FK506), <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi>, and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> were required to induce remission </plain></SENT>
<SENT sid="3" pm="."><plain>Both <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> were eventually well controlled using this regimen </plain></SENT>
<SENT sid="4" pm="."><plain>Our report underscores that caution should be exercised when prescribing immunostimulatory agents in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) and challenges current efforts to stimulate innate immunity as a novel therapeutic concept for IBD </plain></SENT>
</text></document>